This page contains a Flash digital edition of a book.
future focus.

Regener8 – The next phase of development to deliver value for

industry and society By John Fisher and Mike Raxworthy of Regener8

Since Regener8 was established in 2007 it has pursued the objective of promoting the translation of research in regenerative medicine into commercial products.

John Fisher, Director

With the completion of Regener8’s first phase of funding from the RDAs, we have been exploring with our members their strategic needs and with N8, new opportunities for Regener8 to continue to deliver its mission and the new strategic objectives that have been identified. Around 25% of our membership was consulted in this exercise which provided strong support for Regener8.

Mike Raxworthy, Operations Director

In developing our new strategic objectives, we have been helped in our review of strengths and Unique Selling Propositions (USP’s) by a small Task and Finish Team drawn from industry and academic Regener8 members. They have recommended that Regener8’s priorities should continue to be:

(a) the development of translational awareness and capability amongst academic researchers;

(b) addressing and facilitating the interface between university and industry – and particularly bridging the translation gap between Technology Readiness Levels (TRL) 2 and 5;

(c) a focus on collective industry translational barriers (e.g. manufacturing, regulations, safety and efficacy testing, preclinical evaluation, scale-up, clinical development, reimbursement, supply/distribution chain mapping and development and health economics) and the means of overcoming these.

These emphases have led Regener8 to develop particular capability in enabling science and technology, and in services such as networking and collaboration- brokering for regenerative medicine companies, which are supportive of national initiatives in the translation and delivery of regenerative therapies.

These offerings were highly valued by members and also align well with national initiatives such as the forthcoming Cell Therapy TIC. We plan to continue to position Regener8 to maximise these opportunities and will now develop our online resource and information provision to members through roadmaps to advice, expertise, facilities, equipment, suppliers and member benefits.

We will continue to exert an influence beyond the North of England (e.g. as a member of the UK Regenerative Medicine and Stem Cell Networks group and through events such as the Regener8 Annual Meeting). The consultation exercise also allowed the construction of assets maps across Regener8 membership and these will be used to sharpen the offering and the use of resources available to us.

In addition, it was recommended that Regener8 should not be constrained by operating only in the North of England, should expand its membership and offering to members nationally and, indeed, should establish an international membership and collaborations.

Through the consultation, particular strengths were identified for Regener8 in:

• accelerating biomaterial developments • advancing the technologies to support cell therapies • moving RegenMed developments into the clinic • linking the RegenMed community.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36